Off-the-Shelf CAR t cells take on Hard-to-Treat myeloma

NCT ID NCT04093596

Completed Disease control Sponsor: Allogene Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safety and see if adding another drug, nirogacestat, could help the CAR T cells work better. Because this is a disease-control approach and not a cure, patients may still need ongoing management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
City of Hope

Duarte, California, 91010, United States
Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, 44195, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Sarah Cannon/Colorado Blood Cancer Institute

Denver, Colorado, 80218, United States
St. David's South Austin Medical Center

Austin, Texas, 78704, United States
Stanford Cancer Institute

Palo Alto, California, 94305, United States
Texas Transplant Institute

San Antonio, Texas, 78229, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.